HeartSciences Operating Income 2022-2025 | HSCS
HeartSciences operating income from 2022 to 2025. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
|
HeartSciences Annual Operating Income (Millions of US $) |
|
|---|---|
| 2025 | $-8 |
| 2024 | $-6 |
| 2023 | $-6 |
| 2022 | $-5 |
| 2021 | $-3 |
|
HeartSciences Quarterly Operating Income (Millions of US $) |
|
|---|---|
| 2025-10-31 | $-2 |
| 2025-07-31 | $-2 |
| 2025-04-30 | $-2 |
| 2025-01-31 | $-2 |
| 2024-10-31 | $-2 |
| 2024-07-31 | $-2 |
| 2024-04-30 | $-2 |
| 2024-01-31 | $-2 |
| 2023-10-31 | $-2 |
| 2023-07-31 | $-1 |
| 2023-04-30 | $-2 |
| 2023-01-31 | $-1 |
| 2022-10-31 | $-2 |
| 2022-07-31 | $-1 |
| 2022-04-30 | $-2 |
| 2022-01-31 | $-1 |
| 2021-10-31 | $-1 |
| 2021-07-31 | $-1 |
| 2021-04-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.010B | $0.000B |
| Heart Test Laboratories, Inc. d/b/a HeartSciences is a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to expand and improve an ECG's clinical utility. Millions of ECGs are performed every week and the Company's objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. HeartSciences has one of the largest libraries of AI-ECG algorithms and is developing AI-ECG solutions to be made available on either a hardware agnostic cloud-based platform or its proprietary MyoVista? wavECG(TM) device, to help identify cardiovascular disease in any care setting worldwide in a manner to best suit different care providers. HeartSciences' first product candidate for FDA clearance, the MyoVista? wavECG(TM), or the MyoVista(R), is a resting 12-lead ECG that is also designed to provide diagnostic information related to cardiac dysfunction. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $30.189B | 34.91 |
| Tempus AI (TEM) | United States | $9.769B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $5.240B | 42.63 |
| Doximity (DOCS) | United States | $5.221B | 22.18 |
| IRhythm Holdings (IRTC) | United States | $4.719B | 0.00 |
| Privia Health (PRVA) | United States | $2.705B | 169.15 |
| Hinge Health (HNGE) | United States | $2.454B | 0.00 |
| Heartflow (HTFL) | United States | $2.362B | 0.00 |
| 10x Genomics (TXG) | United States | $2.355B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $1.909B | 31.59 |
| Omnicell (OMCL) | United States | $1.664B | 46.34 |
| Azenta (AZTA) | United States | $1.321B | 53.19 |
| Enovis (ENOV) | United States | $1.292B | 6.78 |
| Clover Health Investments (CLOV) | United States | $1.101B | 0.00 |
| Schrodinger (SDGR) | United States | $0.994B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.854B | 0.00 |
| Phreesia (PHR) | United States | $0.736B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.725B | 0.00 |
| Talkspace (TALK) | United States | $0.643B | 129.33 |
| Standard BioTools (LAB) | United States | $0.485B | 0.00 |
| Claritev (CTEV) | United States | $0.428B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.324B | 0.00 |
| Evolent Health (EVH) | United States | $0.318B | 0.00 |
| Carlsmed (CARL) | United States | $0.310B | 0.00 |
| TruBridge (TBRG) | United States | $0.304B | 13.97 |
| Senseonics Holdings (SENS) | United States | $0.304B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.256B | 0.00 |
| CapsoVision (CV) | United States | $0.232B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.228B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.210B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.167B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.158B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.152B | 0.00 |
| CareCloud (CCLD) | United States | $0.104B | 5.70 |
| Outset Medical (OM) | United States | $0.082B | 0.00 |
| American Well (AMWL) | United States | $0.073B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.065B | 0.00 |
| 111 (YI) | China | $0.064B | 0.00 |
| Pulmonx (LUNG) | United States | $0.062B | 0.00 |
| HeartBeam (BEAT) | United States | $0.049B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.042B | 0.00 |
| Precipio (PRPO) | United States | $0.035B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.028B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.020B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.016B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.015B | 0.00 |
| Movano (MOVE) | United States | $0.012B | 0.00 |
| ITonic Holdings (ITOC) | China | $0.007B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.007B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.006B | 0.00 |
| Zhongchao (ZCMD) | China | $0.006B | 0.00 |
| PROFUSA (PFSA) | United States | $0.005B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.001B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.001B | 0.00 |